Alachua’s Life Sciences Ecosystem Raises Over $1.0 Billion in 2020

UF Innovate | Sid Martin Biotech announces the City of Alachua’s life sciences industry has raised more than $1 billion in 2020. The life sciences community has accelerated growth with government grants and contracts, mergers and acquisitions, successful financing rounds, and sales revenue.

Orchard Tech Helps Create Savvy Seniors

Some of the best business ideas begin with family, and 25-year-old Ming Yang’s Orchard Tech, a UF Innovate | The Hub alum that helps Baby Boomers cross the digital divide, is one of them.

Harness Pheromones for Sustainable Pest Control

“Without some method of treatment, about 12% of crops globally would be lost to plant parasitic nematodes,” says Karl Cameron Schiller, co-founder and chief operating officer of bio-tech startup Pheronym. To combat these pests, Schiller and his team are developing non-toxic pesticide solutions that pose fewer risks to the environment.

COVID-19 Fighting Antibodies Developed in Alachua Sent to Clinical Trials

Supporting our troops: an Alachua company works to keep our soldiers safe from COVID-19. Here’s what UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), is doing on the front lines of the pandemic.

Century 22 Solutions Joins Creek Technologies Company’s OASIS Team

UF Innovate | The Hub resident company Century 22 Solutions LLC (C22) formally announced that it joined with Creek Technologies Company’s (CreekTech’s) team pursuing opportunities under the General Services Administration (GSA) for the agency’s One Acquisition Solution for Integrated Services (OASIS) Small Business (SB) Pool 1 Government-Wide Acquisition Contract (GWAC).

Ology Bioservices Signs Built-to-Suit Lab Space, Adding 43,000 Square Feet to Headquarters

Avison Young facilitated a 42,500-square-foot lease agreement between Concept Companies and Ology Bioservices, a UF startup and UF Innovate | Sid Martin Biotech alum, for a new built-to-suit lab space on the heels of a federal government contract for the company to expand production capabilities, including vaccines and therapeutics for COVID-19 once finalized.